New diabetes drug candidate enters human testing

NCT ID NCT06280703

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests an experimental drug called LY3938577 in healthy volunteers and people with type 1 diabetes. The main goals are to see how the body processes the drug and whether it can safely lower blood sugar. The study has four parts, comparing the drug to insulin or placebo, and will last up to 13 weeks per participant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3938577 (an experimental drug given by injection or infusion)
What this could lead to: If successful, this could point toward a new option for managing blood sugar in type 1 diabetes, possibly reducing the need for insulin.
What could go wrong: This is a very early Phase 1 trial with only 118 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

Profil Institut für Stoffwechselforschung
RECRUITING

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.